Mr. Bill Price has been appointed Business Group Director DSM Fibre Intermedates.  Mr. Hans van Suijdam has been appointed Director DSM Research and Engineering. Mr. Emmo Meijer has been appointed Project Director and Chairman of the integration team for DSM Nutritional Products.

DSM has won the Henri Sijthoff Prize for the best Annual Report for the year 2002 in the Dutch AEX listed funds category.

Negative net result in Q3 (EUR 78 million) in line with announcement; considerable improvement of operating profit expected in Q4

Peter Elverding, the Chairman of DSM’s Managing Board of Directors, today presented the DSM People Award for 2003 to the management team of DSM Agro’s Manufacturing organization.

DSM appoints Corporate Vice President DSM China.

Following the closing of the acquisition of Roche Vitamins & Fine Chemicals, DSM remains “on-track and on-schedule” to achieve its Vision 2005 strategy and “may have seen the worst in market conditions now,” according to Peter Elverding, Chairman of DSM’s Managing Board.

DSM and Industriebank LIOF presented their joint initiative Limburg Ventures at the Netherlands Society of Technological Sciences and Engineering’s innovation conference in The Hague today.

DSM has received permission to close its acquisition of Roche Vitamins & Fine Chemicals (R-V&FC).

Agreement between DSM and Foundation for Relatives of Victims of 1975 Disaster

DSM has yesterday been announced as a component of the Dow Jones Sustainability World Index (DJSI). The DJSI World will again include over 300 companies from 22 countries that lead their industry in terms of corporate sustainability.

For the second year in succession, DSM has been named by the European Patent Office (EPO) as the company filing the largest number of biotechnology patent applications in Europe.

At 10.45 a.m. today there was an explosion in a glyoxylic acid production facility at DSM Fine Chemicals in Linz, Austria. The fire that followed the explosion was rapidly extinguished. At the time of the explosion there were no people in the plant.

In the second quarter of 2003 DSM posted an operating profit which, at EUR 85 million, was around the Q1 2003 level, in line with expectations. The operating profit was EUR 17 million (17%) lower than the operating profit from ongoing activities in the second quarter of 2002.

During the last few months DSM and Roche have made good progress with regard to the finalization of the acquisition by DSM of Roche’s Vitamins and Fine Chemicals division (V&FC), for which the parties signed a contract on February 10, last.

DSM, the world’s largest supplier to the pharmaceutical industry, has taken a minority interest (25%) in Chiralix of Nijmegen, the Netherlands.

DSM, one of the world’s largest specialty chemicals providers, which continuously focuses on providing superior services to customers, is announcing today that it has selected Transwide as its standard for land transport execution.

DSM has announced it is to acquire National Starch & Chemical’s Plasticoat® food coating business with effect from July 1st, 2003.

DSM and Rens Blom today signed a sponsorship agreement that will run until the end of the Olympic Games in Athens.

The new recovery drink for athletes developed by DSM produces better average performance levels than a normal, sugar-based sports drink.

DSM is introducing VevoVitall®, a new eco-friendly feed additive for pigs.

DSM has completed its investigation into the causes of the explosion that occurred on 1 April in the gas-fired furnace of Melamine Plant 2 in Geleen (Netherlands).

Dutch researcher Dr. Vincent de Groot today won the first International DSM Award for Chemistry and Technology.

The European Commission today said that they need more time to examine a small part of DSM’s intended acquisition of Roche Vitamins & Fine Chemicals.

The artist Leonne Hendriksen makes soft sculptures in the form of installations, wall objects, costumes and other designs.

DSM has decided to build a large-scale biopharmaceuticals plant in Montreal, Canada.

Bernard van Schaik (51) has been appointed Business Group Director of DSM Pharmaceutical Products (DPP) with effect from 1 May 2003.

Don Verstegen (58) has been appointed Business Group Director of DSM Coating Resins (DCR) with effect from 1 May 2003.

Renso Zwiers (48) has been appointed Business Group Director of DSM Agro with effect from 1 May.

Henk Numan (53) has been appointed Corporate Director Strategic Projects with effect from 1 May 2003.

• Sales up 7%, mainly due to autonomous volume growth (9%).
• Operating profit from ongoing activities 12% higher than in Q1 2002.
• Second-quarter operating profit seems to be developing around the level of the first quarter of 2003.

Three top researchers from DSM’s US subsidiary DSM Desotech have won the DSM Special Invention Reward 2003.

DSM Venturing has invested USD 0.5 million in InMat Inc., a US based innovative materials company active in the area of elastomeric nanocomposite coatings.

DSM has commenced an investigation into the facts and the cause of the explosion at the Melamine plant on Tuesday 1 April 2003. The investigation will cover both the direct cause of the accident and the circumstances leading up to it.

On Tuesday 1 April at 12.15 hours there was an explosion at DSM’s Melamine Plant 2  in Geleen (Netherlands) during work on a gas-fired reactor.

We are all deeply shocked by the accident that occurred at the DSM melamine plant in Geleen (Netherlands) today, in which three people were killed.

At a press conference held in Delft (the Netherlands) today, DSM presented its first Triple P Report, an integrated report on the company’s policy and performance in the fields of People, Planet and Profit.

DSM, the world’s leading supplier to the pharmaceutical industry, is now also supplying technologies and services for the initial development phases of new medicines.

Mr Just Fransen van de Putte (59), currently director of Strategic Projects at DSM, has been appointed director of DSM Limburg BV and DSM Industrial Services BV with effect from 21 February 2003.

• Q4 operating profit EUR 96 million, almost twice as high as in weak Q4 2001 on a comparable basis
• Profit on ordinary activities after taxation in 2002 EUR 349 million (-5%); fourth quarter EUR 74 million (+32%)
• 6% autonomous volume growth in 2002 compared with 2001
• Dividend unchanged: EUR 1.75 per ordinary share

DSM and Roche announced today that the contract to acquire Roche’s vitamins, carotenoids and fine chemicals business has been signed. This transaction is subject to approval by the anti-trust authorities. Roche and DSM anticipate that the closing will take place in the spring of 2003.

DSM Venturing & Business Development has transferred its soil remediation technology PuriSoil® to a new company called Terreco.

DSM Venturing has invested $ 1.5 million in Optiva, Inc., a California-based company that develops Thin Crystal Film (TCF) technology for use in products such as flat panel displays.